According to a recent Reuters article, drug giant Eli Lilly and Co. has requested that the FDA de-authorize its COVID-19 antibody, bamlanivimab. The unique request isn’t linked to safety issues, but in response to new variants of the virus that could be resistant to bamlanivimab when used alone. The government agreed, and stopped distribution of the therapy last month. Facilities that still have supply are being shipped etesevimab to pair with it for a combination treatment that’s more effective.
Eli Lilly Asks FDA to Cancel COVID-19 Antibody Authorization
The pharmaceutical giant will use the antibody as part of a combination treatment for greater efficacy.
Apr 23, 2021
Recommended
Recommended
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
